Binder, Ronald K.

Frangieh, Antonio H.

Templin, Christian

RERO DOC Digital Library

inflammation by positron emission tomography in patients with aortic stenosis.Circulation 2012;125:76–86.25. Angel K, Provan SA, Fagerhol MK, Mowinckel P, Kvien TK, Atar D. Effect of 1-yearanti-TNF-alpha therapy on aortic stiffness, carotid atherosclerosis, and calprotectinin inflammatory arthropathies: a controlled study. Am J Hypertens 2012;25:644–650.26. Brezinski EA, Follansbee MR, Armstrong EJ, Armstrong AW. Endothelial dysfunc-tion and the effects of TNF inhibitors on the endothelium in psoriasis and psoriaticarthritis: a systematic review. Curr Pharm Des 2014;20:513–528.27. Gisondi P, Fantin F, Del GM, Valbusa F, Marino F, Zamboni M, Girolomoni G.Chronic plaque psoriasis is associated with increased arterial stiffness. Dermatology2009;218:110–113.28. Biyik I, Narin A, Bozok MA, Ergene O. Echocardiographic and clinical abnormalitiesin patients with psoriasis. J Int Med Res 2006;34:632–639.29. Shang Q, Tam LS, Yip GW, Sanderson JE, Zhang Q, Li EK, Yu CM. High prevalenceof subclinical left ventricular dysfunction in patients with psoriatic arthritis.J Rheumatol 2011;38:1363–1370.30. Saleh HM, Attia EA, Onsy AM, Saad AA, Abd Ellah MM. Platelet activation: a linkbetween psoriasis per se and subclinical atherosclerosis – a case-control study.Br J Dermatol 2013;169:68–75.31. Khalid U, Ahlehoff O, Gislason GH, Kristensen SL, Skov L, Torp-Pedersen C,Hansen PR. Psoriasis and risk of heart failure: a nationwide cohort study. Eur J HeartFail 2014;16:743–748.32. Kimball AB, Robinson D Jr, Wu Y, Guzzo C, Yeilding N, Paramore C, Fraeman K,Bala M. Cardiovascular disease and risk factors among psoriasis patients in two UShealthcare databases, 2001–2002. Dermatology 2008;217:27–37.33. Yang YW, Keller JJ, Lin HC. Medical comorbidity associated with psoriasis in adults:a population-based study. Br J Dermatol 2011;165:1037–1043.CARDIOVASCULAR FLASHLIGHT. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .doi:10.1093/eurheartj/ehv240Online publish-ahead-of-print 3 June 2015Optical coherence tomography follow-up after bioresorbable in metallicand metallic in bioresorbable stenting: tackling in-stent restenosis in theera of bioresorbable vascular scaffoldsAntonio H. Frangieh, Christian Templin, and Ronald K. Binder*Department of Cardiology, University Heart Center, University Hospital Zu¨rich, Ra¨mistrasse 100, Zu¨rich CH 8091, Switzerland* Corresponding author. Tel: +41 44 255 17 64, Fax: +41 44 255 44 01, Email: ronald.binder@usz.chThis paper was guest edited by Brahmajee Nallamothu (University of Michigan; bnallamo@umich.edu).A 63-year-old woman with stable angina under-went percutaneous coronary intervention ofthe left circumflex coronary artery (LCX) andthe first obtuse marginal branch (OM1) withbiolimus-eluting stents (BES) with the V-stentingtechnique (Panels A and A′). Seven months laterdue to recurrent angina repeat coronary angiog-raphy was performed and revealed in-stent re-stenosis in the proximal segments of both BES.Subsequently, the OM1 lesion was dilated witha paclitaxel drug-coated balloon. The LCX sten-osis was treated with an everolimus eluting bior-esorbable vascular scaffold (BVS) extending intothe proximal LCX segment (bioresorbable inmetallic stenting) (Panels B and B′). A proximaledge dissection (Supplementary material online, Videos—OCT) was managed by implantation of another overlapping BVS in the proximalLCX (Panels J, J′, K, and K′). Three months later the patient presented with recurrent chest pain. Coronary angiography documentedin-stent restenosis in the proximal OM1 (Panel C) that was treated by implantation of a zotarolimus-eluting stent (ZES) extendingfrom OM1 to the proximal LCX (Panel C′) covering the BVS (metallic in bioresorbable stenting).Twenty-seven months after the first intervention the patient reported atypical angina. Because of her extensive history, she was dir-ectly referred for coronary angiography, which showed all stents patent with excellent flow (Panel D). An optical coherence tomographywas performed (Supplementary material online, Videos), which confirmed complete endothelialization, no restenosis, and well-expandedBVS in BES (Panels F and F′) as well as ZES in BVS (Panels H and H′).Although these approaches need further evaluation through clinical trials, this case confirms the feasibility and efficacy of using metallicin bioresorbable and bioresorbable in metallic stenting for the treatment of in-stent restenosis with excellent endothelialization as docu-mented by optical coherence tomography.Supplementary material is available at European Heart Journal online.Published on behalf of the European Society of Cardiology. All rights reserved. & The Author 2015. For permissions please email: journals.permissions@oup.com.A nationwide cohort study 2183

Optical coherence tomography follow-up after bioresorbable in metallic and metallic in bioresorbable stenting: tackling in-stent restenosis in the era of bioresorbable vascular scaffolds

http://doc.rero.ch/record/290336/files/ehv240.pdf

Optical coherence tomography follow-up after bioresorbable in metallic and metallic in bioresorbable stenting: tackling in-stent restenosis in the era of bioresorbable vascular scaffolds

Abstract

Similar works

Full text

Available Versions

RERO DOC Digital Library